Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Department of Justice
Farmers Insurance
Moodys
Teva
Harvard Business School
Fish and Richardson
Medtronic
Boehringer Ingelheim

Generated: July 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LINAGLIPTIN

« Back to Dashboard

Clinical Trials for linagliptin

Trial ID Title Status Sponsor Phase Summary
NCT00309608 Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes Completed Boehringer Ingelheim Phase 2 The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels. In addition, there will be an unblinded treatment arm with glimepiride as add-on therapy to metformin for comparison. The influence of several factors (gender, age, weight, race, etc.) on the bioavailability and efficacy of BI 1356 BS will also be tested in this study.
NCT00328172 Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients Completed Boehringer Ingelheim Phase 2 The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes and insufficient glycemic control. In addition, there will be an open-label treatment arm with metformin for sensitivity measurement with this patient population. Population pharmacokinetics of BI 1356 BS will also be assessed in this study.
NCT00601250 Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control
NCT00602472 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for linagliptin

Condition Name

Condition Name for linagliptin
Intervention Trials
Diabetes Mellitus, Type 2 47
Healthy 25
Type 2 Diabetes 10
Type 2 Diabetes Mellitus 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for linagliptin
Intervention Trials
Diabetes Mellitus 68
Diabetes Mellitus, Type 2 68
Renal Insufficiency 6
Insulin Resistance 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for linagliptin

Trials by Country

Trials by Country for linagliptin
Location Trials
United States 378
Canada 86
Germany 35
Australia 27
Italy 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for linagliptin
Location Trials
Texas 24
California 21
Florida 21
South Carolina 17
Georgia 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for linagliptin

Clinical Trial Phase

Clinical Trial Phase for linagliptin
Clinical Trial Phase Trials
Phase 4 29
Phase 3 37
Phase 2 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for linagliptin
Clinical Trial Phase Trials
Completed 68
Recruiting 17
Active, not recruiting 10
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for linagliptin

Sponsor Name

Sponsor Name for linagliptin
Sponsor Trials
Boehringer Ingelheim 73
Eli Lilly and Company 35
American Diabetes Association 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for linagliptin
Sponsor Trials
Industry 126
Other 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
UBS
Cantor Fitzgerald
Fuji
Federal Trade Commission
Covington
Moodys
Accenture
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.